13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

245 trials found

diseases per page:

Showing 1 to 10 of 245 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05266469 (ClinicalTrials.gov)	May 1, 2022	23/2/2022	Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumabin a Real-World Setting in the Gu ...	Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofa ...	Relapsing Multiple Sclerosis	Other: Ofatumumab;Other: Ocrelizumab	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	100 Years	All	240		NULL
2	NCT05285891 (ClinicalTrials.gov)	April 30, 2022	8/3/2022	Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Randomized, Blinded Discontinuation Trial of Ocrelizumabin Early Relapsing Multiple Sclerosis (AMS05 ...	Multiple Sclerosis	Biological: Ocrelizumab;Drug: Placebo for Ocrelizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence (ACE)	Not yet recruiting	18 Years	55 Years	All	175	Phase 4	NULL
3	NCT05232825 (ClinicalTrials.gov)	March 31, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investiga ...	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical ...	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: Dex ...	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	65 Years	All	232	Phase 3	United States;Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine
4	NCT04998812 (ClinicalTrials.gov)	March 31, 2022	6/8/2021	A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy	A Phase IV Multicenter, Open-Label Study Evaluating B Cell Levels In Infants Potentially Exposed To ...	Multiple Sclerosis;Clinically Isolated Syndrome	Drug: Ocrelizumab	Hoffmann-La Roche	PPD;LabCorp;Illingworth	Recruiting	18 Years	40 Years	Female	44	Phase 4	United States;France;Spain;United Kingdom;Canada;Germany;Italy;Switzerland
5	EUCTR2021-004791-34-NL (EUCTR)	16/03/2022	15/03/2022	Personalized dosing of ocrelizumab in MS	Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumabversus standard ocrelizumabin ...	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ocrevus Product Name: ocrelizumab	VU medical center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	296	Phase 4	Netherlands
6	NCT05269004 (ClinicalTrials.gov)	March 15, 2022	11/2/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of OcrelizumabIn Patients With Multip ...	A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety An ...	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	N/A	All	1300	Phase 3	NULL
7	EUCTR2020-005448-48-CZ (EUCTR)	15/03/2022	05/05/2021	A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical ...	A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGA ...	Multiple Sclerosis (MS) MedDRA version: 21.1;Level: PT;Classification code 10063401;Term: Primary pr ...	Trade Name: Ocrevus Product Name: ocrelizumab Product Code: RO4964913 INN or Proposed INN: Ocrelizumab O ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	232	Phase 3	United States;Czechia;Spain;Ukraine;Turkey;Russian Federation;Italy;France;Czech Republic;Canada;Pol ...
8	NCT05208840 (ClinicalTrials.gov)	February 28, 2022	12/1/2022	A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis	Open-Label Multicenter Study To Determine The Effect Of OcrelizumabOn Leptomeningeal Inflammation In ...	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche	NULL	Recruiting	18 Years	65 Years	All	50	Phase 4	Russian Federation
9	NCT04877457 (ClinicalTrials.gov)	February 15, 2022	30/4/2021	Ocrelizuamb for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated D ...	A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of ...	Radiologically Isolated Syndrome;Multiple Sclerosis	Drug: Ocrelizumab;Other: Placebo	Yale University	Genentech, Inc.	Recruiting	18 Years	40 Years	All	100	Phase 4	United States
10	EUCTR2020-004128-41-BG (EUCTR)	15/02/2022	15/10/2021	A Study to Evaluate Safety and Efficacy of Ocrelizumabin Comparison with Fingolimod in Children and ...	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICAC ...	Relapsing-Remitting Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Ocrevus INN or Proposed INN: Ocrelizumab Other descriptive name: OCRELIZUMAB Trade Name: Gi ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	233	Phase 3	United States;Serbia;Portugal;Greece;Spain;Ukraine;Russian Federation;Italy;Switzerland;France;Denma ...

First Previous1 2 3 4 5…25Next Last